Over the past 11 years, Cambridge Healthtech Institute's Mastering Medicinal Chemistry has grown into the must-attend event for senior level medicinal chemists. This year's conference, held from June 10-11 in Boston focuses on informative, high quality case studies and successful strategies to tackle the problems facing the medicinal chemistry landscape. The 2015 program includes coverage of covalent and irreversible inhibitors, water in drug discovery, hit generation and discovery technologies, the kinome in drug discovery, and the future role of medicinal chemistry. Hear from senior R&D scientists and executives from leading academic institutions and pharma including Novartis, Pfizer, Abbvie, Takeda, Amgen, AstraZeneca, GlaxoSmithKline, Cubist Pharmaceuticals and Bristol Myers Squibb Co.
Pre-Conference Short Course
June 9 | 2:00 – 5:00 PM
Allosteric Modulators of GPCRs, (PAMs NAMs)
Corey Hopkins, Ph.D., Research Assistant Professor, Vanderbilt Center for Neuroscience Drug Discovery
Cody J. Wenthur, Pharm. D., Graduate Student, Department of Pharmacology, Vanderbilt University Medical Center
View Detailed Agenda
Day 1 | Day 2 | Speaker Biographies | Download Brochure
Wednesday, June 10
7:00 am Registration and Morning Coffee
8:00 Chairperson’s Opening Remarks
Stewart L. Fisher, Ph.D., Principal, SL Fisher Consulting, LLC
8:05 Target Validation and Reproducibility - A Chemistry Perspective
Mark Bunnage, Ph.D., Vice President, Worldwide Medicinal Chemistry, Pfizer
Reproducibility of the scientific literature is a topic of significant current interest. This discussion will focus on irreproducibility issues in target validation and what it means for medicinal chemistry.
8:14 So You Want to Improve Your Medicinal Chemistry?
Jeremy J. Edmunds, Ph.D., Director, Immunology Medicinal Chemistry, Abbvie
Once a compound has been made by a medicinal chemist all that remains is to reveal the properties associated with that compound. When one considers the considerable expense that is associated with developing a drug, it is clearly the responsibility of the chemist to ensure that they are preparing the most optimal compound. To achieve this we have focused our efforts within Abbvie medicinal chemistry toward excellence in design and excellence in synthesis. Here we will describe the trials and tribulations of this approach.
8:23 Outsourcing of Medicinal Chemistry
David Bauer, Principal Scientist, Head of Medicinal Chemistry Outsourcing, Amgen
The presentation will give an overview of how leveraging external partnerships is being used at Amgen to support our Medicinal Chemistry organization. The key components of our outsourcing strategy will be discussed.
8:32 Pre-Competitive Collaboration – How AstraZeneca’s Open Innovation Program is Changing the Way We Deliver Medicine to Patients
Pamela Hill, Open Innovation Program Manager, Emerging Innovations, AstraZeneca, R&D Boston
The AstraZeneca Open Innovation platform has been created to help us identify and establish mutually beneficial collaborations that will lead to the discovery and development of new medicines. We provide collaborators with access to late-stage compounds, our compound collection as well as our cheminformatics and screening technologies to validate and publish novel science.
8:40 Panel Q&A with Session Speakers
9:05 The Application of Extended Hückel Theory for Pharmacophore Modeling
Michael Drummond, Ph.D., Applications Scientist, Chemical Computing Group
Pharmacophore models play an essential role in drug discovery. Generating pharmacophore models which encode accurate molecular recognition features are highly dependent on properly defined annotation points. Here we have developed a new approach for pharmacophore modeling which is based on a semi-empirical method using Extended Hückel Theory (EHT). The pharmacophore features generated through the EHT annotation scheme take into account ligand resonance and electron withdrawing effects and are sensitive to non-standard interactions, such as C-H and halogen bond interactions, during pharmacophore screening.
9:35 Small Molecules in Cancer Immunotherapy
Jerry L. Adams, Ph. D., Director, Medicinal Chemistry, Immuno-Oncology & Combinations DPU, GlaxoSmithKline Pharmaceuticals
Immunotherapy for cancer became an effective treatment modality in 2011. The first wave of successful immuno-oncology drugs target T-cell co-receptors by interrupting protein-protein interactions, a mechanism typically unachievable with a small molecule drug. The currently available cancer immunotherapies are biologic in nature, such as antibodies, peptides/proteins and more recently, cells. Nevertheless, modulating the immune system through a small molecule approach offers several advantages which are complimentary and potentially synergistic to biologic modalities. Importantly, the successes of checkpoint inhibition provide direction for further advances in the field of immune-oncology, including what roles small molecule drugs might play. Already clinical trials are underway with small molecule drugs in combination with checkpoint inhibitors. This talk will provide an overview of the strategy for and targets druggable by small molecules.
10:05 Coffee Break in the Exhibit Hall with Poster Viewing
10:50 Kinase Drug Discovery Past, Present, and Future
Mark Bunnage, Ph.D., Vice President, Worldwide Medicinal Chemistry, Pfizer
Over recent years there has been remarkable progress in the medicinal chemistry design of selective protein kinase inhibitors. There are now over 20 kinase inhibitor drugs on the market and, with the recent approval of the JAK kinase inhibitor Xeljanz® (tofacitinib citrate), we are now seeing kinase drugs emerge for indications beyond Oncology. This presentation will discuss current approaches to kinase inhibitor drug discovery and share a perspective on future directions in the field.
11:20 Secreted Protein Kinases as Novel Regulators of the Extracellular Environment
Malcolm Whitman, Ph.D., Professor, Department of Developmental Biology, Harvard School of Dental Medicine; Department of Cell Biology, Harvard Medical School
Secreted protein kinases, targeting serine, threonine and tyrosine, have recently been identified and shown to act in the secretory pathway and outside the cell. These novel kinases are divergent from intracellular kinases and represent a new class of drug targets for the modulation of secreted protein and extracellular matrix function.
11:50 Sponsored Presentation (Opportunity Available)
12:20 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:00 Refreshment Break in the Exhibit Hall with Poster Viewing
1:30 Chairperson’s Remarks
Renato Skerlj, Ph.D., Vice President, Drug Discovery and Preclinical Development, Lysosomal Therapeutics, Inc.
1:35 Akt and RNA Metabolism
Philip N. Tsichlis, M.D., Jane F. Desforges Professor of Medicine, Tufts University School of Medicine
A phosphoproteomics screen of isogenic cell lines expressing different Akt isoforms identified RNA metabolism as an Akt target. The phosphorylation of one of the regulators of RNA metabolism (IWS1) was shown to epigenetically regulate alternative RNA splicing. The role of other Akt targets in RNA processing is under investigation.
2:05 Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell-Specific Spleen Tyrosine Kinase Inhibitors
Matt Lucas, Ph.D., Director, Medicinal Chemistry, Discovery Chemistry and Pharmaceutical Research, Cubist Pharmaceuticals
Tyrosine Kinase Inhibitors’ inhibition of spleen tyrosine kinase (SYK) has attracted much attention as a mechanism for the treatment of cancers and autoimmune diseases. The structure-guided optimization of pyridazine amide SYK inhibitors will be presented, along with an approach that led to the successful identification of non-mutagenic examples with reduced cardiovascular liabilities.
2:35 Solute Carrier Proteins as a Potential Source of New Drug Targets
David Hepworth, Ph.D., Senior Director, Biotherapeutics Chemistry, Worldwide Medicinal Chemistry, Pfizer
Solute carriers (SLCs) are biologically important proteins that control movement of small molecules and ions across membranes. Drug classes that target SLCs include SSRIs and SGLT2 inhibitors. While the SLC family appears to be generally small molecule druggable and is similar in size to the Class A GPCRs, the number drug targets is currently around 10x fewer. The presentation will explore this apparent paradox and provide an overview of the current status of SLC drug discovery.
2:55 Targeting IAP and BCL Protein-Protein Interactions with Small Molecules: Lessons Learned
Brian Aquila, Ph.D., Associate Director, Medicinal Chemistry Oncology Research, AstraZeneca
3:15 Targeting the Arginine Methyltransferases
Kenneth W. Duncan, Ph.D., Associate Director, Molecular Discovery, Epizyme, Inc.
3:35 Modern Drug Research Informatics Applications to CNS, Infectious, Neglected, Rare, and Commercial Diseases
Barry Bunin, Ph.D., CEO, Collaborative Drug Discovery (CDD)
A modern approach to drug discovery informatics in 5 collaborative case studies showcasing the CDD Vault will be explored. The CDD Vault manages biological and chemical private data securely with external data.
3:50 Sponsored Presentation (Opportunity Available)
4:05 Refreshment Break in the Exhibit Hall with Poster Viewing
5:00 PLENARY KEYNOTE PANEL - click here for detailed agenda
6:00 Welcome Reception in the Exhibit Hall with Poster Viewing
7:00 Close of Day
Day 1 | Day 2 | Speaker Biographies | Download Brochure
Thursday, June 11
7:30 am Interactive Breakout Discussion Groups
Each discussion group in this session is led by a moderator/s who ensures focused conversations around key issues. Attendees join a specific group and the small, informal setting facilitates sharing of ideas and active networking.
TABLE: Target Vulnerability and Drug:Target Engagement
Moderator: Stewart L. Fisher, Ph.D., Principal, SL Fisher Consulting, LLC
This roundtable will discuss the concept of target vulnerability - the inherent physiological sensitivity of drug targets to inhibition - and the corresponding levels of target engagement required for efficacy. Themes that will be discussed include the following:
- Factors influencing target vulnerability, such as target turnover rates and rates of pathway flux
- Experimental approaches for assessing target vulnerability
- Emerging techniques for measuring target engagement levels
TABLE: Blood Brain Barrier Penetrance in Drug Discovery for Med Chemists
Moderator: Byron DeLaBarre, Ph.D., President & Chief Scientist,The Consulting Biochemist, LLC
- Best computational methods for predicting BBB property of proposed compounds
- Experimental methods to determine BBB before the clinic - what stages are appropriate for the various approaches?
- Effect of individual patient variance and pathology vs healthy brain on compounds in the clinic
TABLE: Evolving the Kinome in Drug Discovery
Moderator: Renato Skerlj, Ph.D., Vice President, Drug Discovery and Preclinical Development, Lysosomal Therapeutics, Inc.
- Allostery in kinases
- Intermediate kinase states as drug targets
- Secreted Kinase or Extracellular Kinases
- Kinases in the alternate RNA splicing domain
TABLE: Small Molecules and Immunomodulation
Moderator: Jerry L. Adams, Ph. D., Director, Medicinal Chemistry, Immuno-Oncology & Combinations DPU, GlaxoSmithKline Pharmaceuticals
- Rational combinations including small molecule immune regulators - what trials will you be able to run and what should be the therapeutic goal?
- Repurposing of current drugs/targets versus new target discovery
- Effective small molecule cancer immunotherapy without protein agents - is this achievable?
8:35 Chairperson’s Remarks
Byron DeLaBarre, Ph.D., President & Chief Scientist,The Consulting Biochemist, LLC
8:45 Covalent Inhibitors as an Approach for Challenging Targets
Atli Thorarensen, Ph.D., Research Fellow, BioTx Medicinal Chemistry, Pfizer
The pharmaceutical industry has, in the past decade, experienced a decline in innovation of small molecular inhibitors gaining FDA approval. There are many suggestive factors contributing to this decline one of which being that therapeutically important targets are increasingly challenging preventing the identification of potent and selective chemical modulators. The backdrop to this as a potential solution is the increased focus on design and development of covalent inhibitors. Covalent inhibitors provide potential solutions to this difficult target space, but bring additional challenges in medicinal chemistry design due to inhibitors’ intrinsic chemical reactivity. This talk will provide an overview of selective covalent drug discovery efforts and what key insights are required for successful covalent drug design.
9:05 Discovery of Covalent Inhibitors of Nedd4-1 Ubiquitin Ligase: First-in-Class Covalent Inhibitor of HECT E3s
Alexander Statsyuk, Ph.D., Assistant Professor, Chemistry Department, Northwestern University
We have developed a novel fragment-based drug discovery technology which we call irreversible tethering (J. Med. Chem. 2014, 57(11):4969-74). We subsequently used this technology and discovered covalent small molecule inhibitor of Nedd4-1 ubiquitin ligase, an enzyme which is a promising drug target to treat Ebola virus infections, IGF-1 driven human cancers, and degrades α-synuclein. Remarkably, the developed inhibitor of Nedd4-1 is a first known covalent inhibitor of protein-protein interactions, and is the first known inhibitor of E3 ligase processivity. We will discuss the mechanism of action of Nedd4-1 inhibitor, such as switching Nedd4-1 mediated polyubiquitin chain growth from processive to distributive.
9:25 Direct and Synergistic Inhibition of the HCV NS5A Replication Complex
Makonen Belema, Ph.D., Senior Principal Scientist, Discovery Chemistry, Bristol Myers Squibb Co.
The NS5A protein plays multifunctional roles in the hepatitis C virus replication cycle, and its inhibitors are integral components of a promising combination of HCV therapies that secured regulatory approvals recently. Key aspects of the medicinal chemistry effort that optimized a phenotype screen hit to the first-in-class NS5A inhibitor daclatasvir and highlights of mode-of-action studies that revealed considerable synergistic interaction between two distinct classes of NS5A-interacting molecules will be discussed.
9:55 Hit Generation Technologies – From DNA-Encoded Libraries & Phenotypic Screens, to New Chemical Space
Jörg Holenz, Ph.D., Director, Discovery and Preclinical Sciences, Project Leader, AstraZeneca Pharmaceuticals LP
Lead Generation is defining the quality of chemical assets and - given this importance - has undergone significant changes. New hit generation techniques have been added to the pool, and only by cleverly combining these, the challenge to drug novel demanding targets will be met. This lecture will present learnings from successful lead generation case histories.
10:15 Accounting for Water Energetics in Drug Design
Michelle Lynn Hall, Ph.D., Senior Applications Scientist, Schrödinger
Water plays a ubiquitous role in biology and is critical in understanding molecular recognition. While the importance of water is greatly appreciated, a detailed understanding of how to incorporate water into the drug design process has been elusive. For example, crystallography provides the location of a subset of water molecules but cannot place waters throughout the entire binding site. We present strategies for deciding whether it is better to displace, avoid, or bridge a given water molecule once insight into hydration site energetics are in hand.
10:45 Coffee Break in the Exhibit Hall with Poster Viewing
11:30 Triage of High-Throughput Screening Hits: A PAIN in the Assay
Jonathan B. Baell, Ph.D., Director, Australian Translational Medicinal Chemistry Laboratory and Professor, Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Science, Monash Institute of Pharmaceutical Sciences
Mathematically, a standard hit rate of say 0.7% necessarily furnishes more false positives from a high throughput screen than the few (if any) real ligands for that target that may lurk within the set of hits identified. Disturbingly, the false positives can appear to be selective and more potent than real and optimizable compounds and are often pursued only to result in inevitable failure and waste of resources. This talk will outline some personal experiences and reflections along with advice on how to efficiently identify problematic screening hits.
11:50 Time-Average Solvation Distributions in Drug Design: A Holistic Approach to Drug Discovery, from Binding Kinetics to Dynamic Modeling
José Duca, Ph.D., Global Head, Computer-Aided Drug Discovery, Novartis Institutes for BioMedical Research, Inc.
Water is the most important organic molecule in nature and its role in binding processes has been recently made more evident to the computational and medicinal chemistry communities. Our lab has developed a theory from first principles that links solvation to binding kinetics at a molecular level. This allows us to design molecules with desired kinetic profiles, disrupt or enhance specific proton translocation pathways or recapitulate biology from a kinetic viewpoint. We use a comprehensive approach to design chemical matter with optimized pharmaco(binding)kinetics, redefining the role of computational medicinal chemistry in drug discovery.
12:10 pm Designing Water-Soluble Molecules in Drug Discovery
Michael A. Walker, Ph.D., Principal Scientist, Medicinal Chemistry, Bristol-Myers Squibb Pharmaceutical Research and Development
Aqueous solubility is a major issue in the development of a drug since it plays a central role in bioavailability. A number of strategies have been applied by medicinal chemists in order to rationally design molecules which exhibit appropriate solubility. A majority of these approaches are focused on reducing the hydrophobicity of the molecule. This talk will draw upon the literature and from the presenters own work to provide examples where solubility was increased in unexpected ways.
12:30 Close of Conference